AU2001283139A1 - Method of treating estrogen receptor positive carcinoma - Google Patents

Method of treating estrogen receptor positive carcinoma

Info

Publication number
AU2001283139A1
AU2001283139A1 AU2001283139A AU8313901A AU2001283139A1 AU 2001283139 A1 AU2001283139 A1 AU 2001283139A1 AU 2001283139 A AU2001283139 A AU 2001283139A AU 8313901 A AU8313901 A AU 8313901A AU 2001283139 A1 AU2001283139 A1 AU 2001283139A1
Authority
AU
Australia
Prior art keywords
estrogen receptor
receptor positive
treating estrogen
positive carcinoma
carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001283139A
Inventor
Philip Frost
Lee Martin Greenberger
Tammy Michelle Sadler
Yixian Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22840171&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2001283139(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by American Home Products Corp filed Critical American Home Products Corp
Publication of AU2001283139A1 publication Critical patent/AU2001283139A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
AU2001283139A 2000-08-11 2001-08-06 Method of treating estrogen receptor positive carcinoma Abandoned AU2001283139A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22432600P 2000-08-11 2000-08-11
US60/224,326 2000-08-11
PCT/US2001/024615 WO2002013802A2 (en) 2000-08-11 2001-08-06 Method of treating estrogen receptor positive carcinoma

Publications (1)

Publication Number Publication Date
AU2001283139A1 true AU2001283139A1 (en) 2002-02-25

Family

ID=22840171

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001283139A Abandoned AU2001283139A1 (en) 2000-08-11 2001-08-06 Method of treating estrogen receptor positive carcinoma

Country Status (15)

Country Link
US (1) US6511986B2 (en)
EP (1) EP1318837B1 (en)
JP (1) JP2004507465A (en)
CN (1) CN100448487C (en)
AR (1) AR033555A1 (en)
AT (1) ATE278421T1 (en)
AU (1) AU2001283139A1 (en)
CA (1) CA2416976C (en)
DE (1) DE60106281T2 (en)
DK (1) DK1318837T3 (en)
ES (1) ES2228932T3 (en)
HK (1) HK1056687A1 (en)
MX (1) MXPA03001245A (en)
PT (1) PT1318837E (en)
WO (1) WO2002013802A2 (en)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309826B1 (en) * 1997-05-23 2001-10-30 Ginette Serrero 88kDa tumorigenic growth factor and antagonists
US8512960B2 (en) * 1997-05-23 2013-08-20 A&G Pharmaceutical, Inc. 88kDa tumorigenic growth factor and antagonists
US6881548B2 (en) * 1997-05-23 2005-04-19 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy
US7091047B2 (en) * 1997-05-23 2006-08-15 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity
US20030215445A1 (en) 1997-05-23 2003-11-20 Ginette Serrero Methods and compositions for inhibiting the growth of hematopoietic malignant cells
US6720159B1 (en) 1997-12-16 2004-04-13 A&G Pharmaceutical, Inc. 88KDA tumorigenic growth factor and antagonists
US20100111928A1 (en) * 1997-05-23 2010-05-06 A & G Pharmaceutical, Inc. Methods and kits for diagnosis tumorgenicity
US7617145B1 (en) * 2000-10-24 2009-11-10 Worldwide Farm Equipment Auctions.Com Ltd. Adaptive bidding increments in an online auction system
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
AU2016206379B2 (en) * 2001-02-19 2017-09-14 Novartis Ag Cancer Treatment
PT3351246T (en) 2001-02-19 2019-06-07 Novartis Pharma Ag Rapamycin derivative for the treatment of a solid tumor associated with deregulated angiogenesis
AU2011226833B9 (en) * 2001-02-19 2014-07-03 Novartis Ag Cancer treatment
US7875612B2 (en) 2001-04-24 2011-01-25 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
PL211339B1 (en) * 2001-07-09 2012-05-31 Zonagen Methods and materials for the treatment of testosterone deficiency in men
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
AU2003210787B2 (en) 2002-02-01 2009-04-23 Medinol Ltd. Phosphorus-containing compounds & uses thereof
ATE426414T1 (en) * 2002-05-15 2009-04-15 Endocyte Inc VITAMIN-MITOMYCIN CONJUGATES
US7411045B2 (en) * 2002-11-19 2008-08-12 A&G Pharmaceutical, Inc. Autocrine growth factor receptor antibodies and methods
TWI367096B (en) 2003-01-27 2012-07-01 Endocyte Inc Vitamin-receptor binding drug delivery conjugates and pharmaceutical compositions
US7651854B2 (en) * 2003-02-26 2010-01-26 A & G Pharmaceutical, Inc. Methods for increasing the proliferation of B cells
UA83484C2 (en) * 2003-03-05 2008-07-25 Уайт Method for treating breast cancer using combination of rapamycin derivative and aromatase inhibitor, pharmaceutical composition
MXPA05010582A (en) * 2003-04-22 2005-11-23 Wyeth Corp Antineoplastic combinations.
JP2007524622A (en) * 2003-06-23 2007-08-30 エイアンドジー ファーマスーティカルズ インコーポレイテッド Compositions and methods for restoring tumor cell sensitivity to anti-cancer therapy and inducing apoptosis
BRPI0412916A (en) * 2003-07-25 2006-09-26 Wyeth Corp lyophilized cci-779 formulations
EP1660010B1 (en) * 2003-08-01 2013-07-24 A & G Pharmaceutical, Inc. Compositions and methods for restoring sensitivity to treatment with her2 antagonists
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2006012527A1 (en) * 2004-07-23 2006-02-02 Endocyte, Inc. Bivalent linkers and conjugates thereof
EP1804779A1 (en) * 2004-10-28 2007-07-11 Wyeth Use of an mtor inhibitor in treatment of uterine leiomyoma
DE602006021142D1 (en) 2005-02-03 2011-05-19 Gen Hospital Corp METHOD FOR THE TREATMENT OF GEFITINIB-RESISTANT CANCER
JP2008533007A (en) 2005-03-07 2008-08-21 ワイス Oxepane isomer of 42-O- (2-hydroxy) ethyl-rapamycin
CN101175757B (en) * 2005-03-16 2012-11-14 恩多塞特公司 Synthesis and purification of pteroic acid and conjugates thereof
RU2413508C2 (en) * 2005-03-22 2011-03-10 Репрос Терапьютикс Инк. Trans-clomiphene dosing regimen
US20080280937A1 (en) * 2005-08-19 2008-11-13 Christopher Paul Leamon Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives
KR20130113543A (en) * 2005-08-19 2013-10-15 엔도사이트, 인코포레이티드 Multi-drug ligand conjugates
CN103110948A (en) 2005-11-04 2013-05-22 惠氏公司 Antineoplastic combinations with mTOR inhibitor,herceptin, and/or HKI-272
DE102006011507A1 (en) * 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Active substance-loaded nanoparticles based on hydrophilic proteins
WO2008101231A2 (en) * 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
EP2481427A1 (en) * 2007-03-14 2012-08-01 Endocyte, Inc. Folate-Tubulysin conjugates
RU2523909C2 (en) * 2007-06-25 2014-07-27 Эндосайт, Инк. Conjugates, containing hydrophilic spacers of linkers
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
US20090076060A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched temsirolimus
UA96076C2 (en) * 2007-10-16 2011-09-26 Репрос Терапьютикс Инк. Use of trans-clomiphene
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US9187521B2 (en) 2007-10-25 2015-11-17 Endocyte, Inc. Tubulysins and processes for preparing
DK2656844T3 (en) 2008-06-17 2015-03-02 Wyeth Llc ANTINEOPLASTIC COMBINATIONS CONTAINING HKI-272 AND VINORELBINE
CN105963313A (en) 2008-08-04 2016-09-28 惠氏有限责任公司 Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
AU2010234968B2 (en) 2009-04-06 2015-05-14 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
CA2800673A1 (en) 2010-06-10 2011-12-15 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
UA113291C2 (en) 2011-08-04 2017-01-10 TRANSCLOMYPHENE METABOLITES AND THEIR APPLICATIONS
US9187460B2 (en) 2011-12-14 2015-11-17 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
EA201590622A1 (en) 2012-10-16 2015-10-30 Эндосайт, Инк. CONJUGATES FOR DELIVERY OF MEDICINES CONTAINING NOT MEETING IN THE NATURE OF AMINO ACID AND METHODS OF APPLICATION
MX2015005160A (en) 2012-11-02 2015-07-17 Repros Therapeutics Inc Trans-clomiphene for use in cancer therapy.
RU2560708C1 (en) * 2014-03-24 2015-08-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт клинической и экспериментальной лимфологии" Сибирского отделения Российской академии медицинских наук (ФГБУ "НИИКЭЛ" СО РАМН) Method for differentiation stage-related hepatocarcinoma cells exposure to lithium nanopreparations
HUE055321T2 (en) 2015-10-01 2021-11-29 Olema Pharmaceuticals Inc Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs
US10118910B2 (en) 2015-12-09 2018-11-06 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective estrogen receptor downregulators
CN109562113A (en) 2016-05-10 2019-04-02 C4医药公司 Loop coil degron body for target protein degradation
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN109789143A (en) 2016-07-01 2019-05-21 G1治疗公司 Antiproliferative based on pyrimidine
ES2909576T3 (en) 2016-10-11 2022-05-09 Univ Duke Lasofoxifene treatment of ER+ breast cancer
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
CN110177554B (en) 2017-01-06 2023-06-02 G1治疗公司 Combination therapy for the treatment of cancer
CN110461853A (en) 2017-02-10 2019-11-15 G1治疗公司 Benzothiophene estrogenic agents
CN110913861B (en) 2017-06-29 2024-01-09 G1治疗公司 Morphological forms of G1T38 and methods of making the same
CN112261937B (en) 2018-04-10 2023-11-14 杜克大学 Lasofoxifene treatment of breast cancer
CN113453679A (en) 2018-12-20 2021-09-28 C4医药公司 Targeted protein degradation
WO2024030968A1 (en) 2022-08-03 2024-02-08 Brystol-Myers Squibb Company Compounds for modulating ret protein

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5023264A (en) 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
US5023263A (en) 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
US5221670A (en) 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5130307A (en) 1990-09-28 1992-07-14 American Home Products Corporation Aminoesters of rapamycin
US5233036A (en) 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5162333A (en) 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
US5177203A (en) 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5480989A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5489680A (en) 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5480988A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5302584A (en) 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5411967A (en) 1992-10-13 1995-05-02 American Home Products Corporation Carbamates of rapamycin
US5434260A (en) 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5262423A (en) 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5260300A (en) 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5504091A (en) 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
US5373014A (en) 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5378836A (en) 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5391730A (en) 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5385910A (en) 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5385908A (en) 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5385909A (en) 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5389639A (en) 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5463048A (en) 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5491231A (en) 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5563145A (en) 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
DE19624668A1 (en) * 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Use of pyridylalkane, pyridylalken or pyridylalkynamides
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors

Also Published As

Publication number Publication date
WO2002013802A2 (en) 2002-02-21
CA2416976A1 (en) 2002-02-21
PT1318837E (en) 2004-12-31
US20020045638A1 (en) 2002-04-18
ES2228932T3 (en) 2005-04-16
CA2416976C (en) 2008-05-20
ATE278421T1 (en) 2004-10-15
HK1056687A1 (en) 2004-02-27
DE60106281D1 (en) 2004-11-11
MXPA03001245A (en) 2003-05-27
WO2002013802A3 (en) 2003-03-27
EP1318837B1 (en) 2004-10-06
DE60106281T2 (en) 2005-02-24
AR033555A1 (en) 2003-12-26
DK1318837T3 (en) 2005-01-10
CN100448487C (en) 2009-01-07
CN1446106A (en) 2003-10-01
EP1318837A2 (en) 2003-06-18
US6511986B2 (en) 2003-01-28
JP2004507465A (en) 2004-03-11

Similar Documents

Publication Publication Date Title
AU2001283139A1 (en) Method of treating estrogen receptor positive carcinoma
AU2001231223A1 (en) Therapeutic method for reducing angiogenesis
AU2000242834A1 (en) Method and terminal for inputting instructions
AU2001293936A1 (en) Association of the CB1 receptor antagonist and sibutramin, for treating obesity
AU2001259056A1 (en) Method for selectively inhibiting ghrelin action
AU1740900A (en) Method of inhibiting angiogenesis
AU2001227966A1 (en) Methods for treating tumors
AU3263901A (en) Methods for treating pervasive development disorders
EP1176964B8 (en) Uses of et743 for treating cancer
AU1952601A (en) Estrogens for treating als
AU3869200A (en) Method and composition for masking mineral taste
AU2695300A (en) Waste treating method
AU2001237939A1 (en) Methods for treating glaucoma
AU2001253836A1 (en) Method of treating cancer
AU5109800A (en) Digestion method for pulp
AU2002241670A1 (en) Method for treating glaucoma IB
AU7750100A (en) Method for the treatment of obesity
AU7363000A (en) Method for reducing the risk of cancer
AU2001267531A1 (en) Method and installation for drying sludge
AUPQ904100A0 (en) Method of encryption
AU2002233144A1 (en) Method and installation for grinding waste
AU2222900A (en) Extraction material and method for determination of gamma-hydroxybutyrate
AU2001238179A1 (en) Method and compositions for treating hepatocellular cancer
AU7328100A (en) Document, method of its preparation and apparatus for authenticating it
AU2001232534A1 (en) Means and method for heating